Osteopenia in patients infected by the human immunodeficiency virus. A case control study |
| |
| Authors: | Loiseau-Pérès S Delaunay C Poupon S Lespessailles E Ballouche N Arsac P Benhamou C L |
| |
| Affiliation: | 1. Institut de Prévention et de Recherche sur l’Ostéoporose, Equipe INSERM-ERIT M 0101, Hôpital Porte Madeleine BP 2439 45032 Orléans Cedex, France;2. Service de Médecine Interne, Centre Hospitalier Régional d’Orléans, Hôpital Porte Madeleine BP 2439 45032 Orléans Cedex, France;1. Pôle gynéco-obstétrique-reproduction humaine, CHU Estaing, CHU de Clermont-Ferrand, 1, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand cedex 1, France;2. Pôle des spécialités médicales, médecine interne, CHU Estaing, CHU de Clermont-Ferrand, 1, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand cedex 1, France;3. Département de biostatistiques, CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France;4. Pôle des ressources interventionnelles, anesthésie-réanimation, CHU Estaing, CHU de Clermont-Ferrand, 1, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand cedex 1, France;5. R2D2-EA7281, faculté de médecine, université d’Auvergne, place Henri-Dunant, 63000 Clermont-Ferrand, France;1. Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy;2. Division of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy;3. School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa;4. Department of Infectious and Tropical Diseases and CIC 1413, INSERM, University Hospital, Nantes, France;5. HIV Unit, University Hospital 12 de Octubre, Imas12, Universidad Complutense de Madrid, Madrid, Spain;6. Infectious Diseases Unit, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain;7. Department of Infectious Diseases, Saint Louis Hospital, University Paris Diderot, Paris, France;8. Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK;9. Gilead Sciences, Foster City, CA, USA;1. Department of Obstetrics and Gynecology, MacKay Memorial Hospital, Taipei, Taiwan;2. Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan;3. School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan;4. Institute of Clinical and Community Health Nursing, National Yang-Ming University, Taipei, Taiwan;5. Department of Obstetrics and Gynecology, School of Medicine, National Yang-Ming University, Taipei, Taiwan;6. Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung, Taiwan;7. Department of Obstetrics and Gynecology, Taipei Chang Gung Memorial Hospital, Taipei, Taiwan;8. College of Medicine, Chang Gung University, Taoyuan, Taiwan;9. Genephile Bioscience Laboratory, Ko''s Obstetrics and Gynecology, Taipei, Taiwan;10. Gene Biodesign Co. Ltd, Taipei, Taiwan;1. Center for Imaging of Neurodegenerative Diseases, San Francisco Veterans Affairs Medical Center, 4150 Clement Street, 114M, San Francisco, CA 94121, United States;2. Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States;3. Department of Psychiatry, University of California San Francisco, San Francisco, CA, United States;1. Scuola di Specializzazione in Radiodiagnostica, Università degli Studi di Milano, via Festa del Perdono 7, 20122 Milano, Italy;2. Mineralometria Ossea Computerizzata e Ambulatorio Malattie Metabolismo Minerale e Osseo, Servizio di Medicina Nucleare, IRCCS Fondazione Ca’Granda Ospedale Maggiore Policlinico, via Francesco Sforza 9, 20122 Milano, Italy;3. Servizio di Radiologia, IRCCS Policlinico San Donato, via Morandi 30, 20097 San Donato Milanese, Italy;4. Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Mangiagalli 31, 20100 Milano, Italy;1. Department of Physiology & Pharmacology, Thomas J Long School of Pharmacy and Health Sciences, University of the Pacific, 3601 Pacific Avenue, Stockton, CA 95211, USA;2. Research Center for Antibody-based Drug, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, People''s Republic of China |
| |
| Abstract: | ![]()
Summary - In the last few years, the use of highly active antiretroviral therapy has radically modified the prognosis of human immunodeficiency virus (HIV) infection. Osteonecrosis and osteoporosis are among the bone complications recently described in HIV-infected patients. We report a preliminary study comparing 47 HIV-infected patients (31 men and 16 women) to 47 age- and sex-matched controls. Bone mineral density was lower in patients than in controls: in men, 0.919 +/- 0.120 g/cm2 vs. 1.010 +/- 0.139 g/cm2 (P = 0.01) at the total hip and 0.948 +/- 0.100 g/cm2 vs. 1.043 +/- 0.117 g/cm2 (P = 0.0008) at the lumbar spine; in women, 0.912 +/- 0.149 g/cm2 vs. 0.968 +/- 0.090 g/cm2 at the total hip (P = 0.17) and 0.989 +/- 0.152 g/cm2 vs. 1.080 +/- 0.097 g/cm2 (P = 0.01) at the lumbar spine. HIV-infected males were more likely to have osteopenia and osteoporosis, as compared to the male controls (19 vs. 14 and 4 vs. 1, respectively, P = 0.02). None of the women had osteoporosis; nine HIV-infected women and one female control had osteopenia (P = 0.003). No fractures were recorded. In this preliminary study, no evidence supporting a relationship between bone loss and protease inhibitor treatment was found. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
